Safety and preliminary clinical activity of NVL-520, a highly selective ROS1 inhibitor, in patients with advanced ROS1 fusion-positive solid tumors

A. Drilon; B. Besse; D. R. Camidge; S. H.I. Ou; S. M. Gadgeel; M. L. Johnson; A. Calles; M. J. de Miguel; A. I. Spira; E. Felip; G. Lopes; A. J. van der Wekken; Y. Y. Elamin; J. Green; Y. Sun; J. Soglia; V. W. Zhu; J. J. Lin

doi:10.1016/S0959-8049(22)00821-8

Safety and preliminary clinical activity of NVL-520, a highly selective ROS1 inhibitor, in patients with advanced ROS1 fusion-positive solid tumors

A. Drilon, B. Besse, D. R. Camidge, S. H.I. Ou, S. M. Gadgeel, M. L. Johnson, A. Calles, M. J. de Miguel, A. I. Spira, E. Felip, G. Lopes, A. J. van der Wekken, Y. Y. Elamin, J. Green, Y. Sun, J. Soglia, V. W. Zhu, J. J. Lin

Thoracic Head & Neck Medical Oncology

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Original language	English (US)
Pages (from-to)	S6-S7
Journal	European Journal of Cancer
Volume	174
DOIs	https://doi.org/10.1016/S0959-8049(22)00821-8
State	Published - Oct 2022

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1016/S0959-8049(22)00821-8

Cite this

Drilon, A., Besse, B., Camidge, D. R., Ou, S. H. I., Gadgeel, S. M., Johnson, M. L., Calles, A., de Miguel, M. J., Spira, A. I., Felip, E., Lopes, G., van der Wekken, A. J., Elamin, Y. Y., Green, J., Sun, Y., Soglia, J., Zhu, V. W., & Lin, J. J. (2022). Safety and preliminary clinical activity of NVL-520, a highly selective ROS1 inhibitor, in patients with advanced ROS1 fusion-positive solid tumors. European Journal of Cancer, 174, S6-S7. https://doi.org/10.1016/S0959-8049(22)00821-8

Drilon, A, Besse, B, Camidge, DR, Ou, SHI, Gadgeel, SM, Johnson, ML, Calles, A, de Miguel, MJ, Spira, AI, Felip, E, Lopes, G, van der Wekken, AJ, Elamin, YY, Green, J, Sun, Y, Soglia, J, Zhu, VW & Lin, JJ 2022, 'Safety and preliminary clinical activity of NVL-520, a highly selective ROS1 inhibitor, in patients with advanced ROS1 fusion-positive solid tumors', European Journal of Cancer, vol. 174, pp. S6-S7. https://doi.org/10.1016/S0959-8049(22)00821-8

@article{87d76533a6424b10b434aba09a855aa0,

title = "Safety and preliminary clinical activity of NVL-520, a highly selective ROS1 inhibitor, in patients with advanced ROS1 fusion-positive solid tumors",

author = "A. Drilon and B. Besse and Camidge, {D. R.} and Ou, {S. H.I.} and Gadgeel, {S. M.} and Johnson, {M. L.} and A. Calles and {de Miguel}, {M. J.} and Spira, {A. I.} and E. Felip and G. Lopes and {van der Wekken}, {A. J.} and Elamin, {Y. Y.} and J. Green and Y. Sun and J. Soglia and Zhu, {V. W.} and Lin, {J. J.}",

year = "2022",

month = oct,

doi = "10.1016/S0959-8049(22)00821-8",

language = "English (US)",

volume = "174",

pages = "S6--S7",

journal = "European Journal of Cancer",

issn = "0959-8049",

publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Safety and preliminary clinical activity of NVL-520, a highly selective ROS1 inhibitor, in patients with advanced ROS1 fusion-positive solid tumors

AU - Drilon, A.

AU - Besse, B.

AU - Camidge, D. R.

AU - Ou, S. H.I.

AU - Gadgeel, S. M.

AU - Johnson, M. L.

AU - Calles, A.

AU - de Miguel, M. J.

AU - Spira, A. I.

AU - Felip, E.

AU - Lopes, G.

AU - van der Wekken, A. J.

AU - Elamin, Y. Y.

AU - Green, J.

AU - Sun, Y.

AU - Soglia, J.

AU - Zhu, V. W.

AU - Lin, J. J.

PY - 2022/10

Y1 - 2022/10

UR - http://www.scopus.com/inward/record.url?scp=85140461418&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85140461418&partnerID=8YFLogxK

U2 - 10.1016/S0959-8049(22)00821-8

DO - 10.1016/S0959-8049(22)00821-8

M3 - Article

AN - SCOPUS:85140461418

SN - 0959-8049

VL - 174

SP - S6-S7

JO - European Journal of Cancer

JF - European Journal of Cancer

ER -

Safety and preliminary clinical activity of NVL-520, a highly selective ROS1 inhibitor, in patients with advanced ROS1 fusion-positive solid tumors

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this